[1] | Eremkina A.K., Dzeranova L.K., Pigarova E.K., Mokrysheva N.G., Dedov I.I. Morphofunctional features of hormonally inactive pituitary adenomas. Archives of Pathology, 1, 2019 https://doi.org/10.17116/patol20198101171. |
[2] | Lipatenkova A.K., Dzeranova L.K., Pigarova E.A., Astafieva L.I., Grigoriev A.Yu., Shishkina L.V., Cherebilo V.Yu., Ektova A.P. “Silent” pituitary adenomas: review of the literature and description of a series of clinical cases. Obesity and metabolism. 2015; 12(2): 40-46. |
[3] | Asa Sylvia, Ezzat Shereen. The Pathogenesis of Pituitary Tumors. 2009. 4: 97–126 The Annual Review of Pathology: Mechanisms of Disease is online at pathmechdis.annualreviews.org. This article’s doi: 10.1146/annurev.pathol.4.110807.092259. |
[4] | Agustsson TT, Baldvinsdottir T, Jonasson JG, Olafsdottir E, Steinthorsdottir V, Sigurdsson G, et al. The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study. European journal of endocrinology / European Federation of Endocrine Societies. 2015; 173(5): 655-64. |
[5] | Brochier S, Galland F, Kujas M, Parker F, Gaillard S, Raftopoulos C, Young J, Alexopoulou O, Maiter D, Chanson P. Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: a study of 142 patients. Eur J Endocrinol. 2010; 163(2): 193-200. https://doi.org/10.1530/EJE-10-0255. |
[6] | Daly AF, Tichomirowa MA, Beckers A: The epidemiology andgenetics of pituitary adenomas. Best Pract Res ClinEndocrinolMetab 2009, 23:543-54. |
[7] | Das B, Batool S, Khoja A, Islam N. Presentation, management, and outcomes of nonfunctioning pituitary adenomas: An experience from a developing country. Cureus. 2019; 11(9): e5759. DOI: 10.7759/cureus.5759. |
[8] | Dashwood Rh, Ho E. Dietary histone deacetylase inhibitors: from cells to mice to man. Semin Cancer Biol. 2007; 17(5): 363–369. |
[9] | Di Chiro G, Nelson KB. The volume of the sella turcica. Am J Roentgenol Radium Ther Nucl Med 1962; 87:989-1008. |
[10] | Druesne N, Pagniez A, Mayeur C, et al. Diallyl disulfide (DADS) increases histone acetylation and p21(waf1/cip1) expression in human colon tumor cell lines. Carcinogenesis. 2004; 25(7): 1227–1236. |
[11] | Greenman Y, Stern N. Non-functioning pituitary adenomas. Best Pract Res Clin Endocrinol Metab. 2009; 23(5): 625-638. https://doi.org/10.1016/j.beem.2009.05.005 |
[12] | Gonzalez S, Huerta Jm, Alvarez-Uria J, Fernandez S, Patterson Am, Lasheras C. Serum selenium is associated with plasma homocysteine concentrations in elderly humans. J Nutr. 2004; 134(7): 1736–1740. |
[13] | Giovannucci E. Epidemiologic studies of folate and colorectal neoplasia: a review. J Nutr. 2002; 132(8 Suppl): 2350S–2355S. |
[14] | James M. Provenzale. Approaches to Imaging of the Sella: Notes on “The Volume of the Sella Turcica” American Journal of Roentgenology 2006 186:4, 931-932. |
[15] | Jacob Ra, Gretz Dm, Taylor Pc, et al. Moderate folate depletion increases plasma homocysteine and decreases lymphocyte DNA methylation in postmenopausal women. J Nutr. 1998; 128(7): 1204–1212. |
[16] | Johnson It, Belshaw Nj. Environment, diet and CpG island methylation: epigenetic signals in gastrointestinal neoplasia. Food Chem Toxicol. 2008; 46(4): 1346–1359. |
[17] | Kim Jm, Hong K, Lee Jh, Lee S, Chang N. Effect of folate deficiency on placental DNA methylation in hyperhomocysteinemic rats. J Nutr Biochem. 2009; 20(3): 172–176. |
[18] | Mayson SE, Snyder PJ. Silent pituitary adenomas. Endocrinology and metabolism clinics of North America. 2015; 44(1): 79-87. |
[19] | Nakahata Y, Grimaldi B, Sahar S, Hirayama J, Sassone-Corsi P. Signaling to the circadian clock: plasticity by chromatin remodeling. Curr Opin Cell Biol. 2007; 19 (2): 230–237. |
[20] | Rampersaud Gc, Kauwell Gp, Hutson Ad, Cerda Jj, Bailey Lb. Genomic DNA methylation decreases in response to moderate folate depletion in elderly women. Am J Clin Nutr. 2000; 72(4): 998–1003. |
[21] | Ross Sa, Dwyer J, Umar A, et al. Introduction: diet, epigenetic events and cancer prevention. Nutr Rev. 2008; 66(Suppl 1): S1–6. |
[22] | Sadik Z.H.A., Voormolen E.H.J., P.R.A.M. Depauw, B. Burhani, W.A. Nieuwlaat, J. Verheul, S. Leenstra, R. Fleischeuer, P.E.J. Hanssens. Treatment of Nonfunctional Pituitary Adenoma Postoperative Remnants: Adjuvant or Delayed Gamma Knife Radiosurgery? World Neurosurg. (2017) 100: 361-368. http://dx.doi.org/10.1016/j.wneu.2017.01.028. |
[23] | Saeger W, Lüdecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol. 2007 Feb; 156(2): 203-16. doi: 10.1530/eje.1.02326. PMID: 17287410]. |
[24] | Sanmillan JL, Torres-Diaz A, Sanchez-Fernandez JJ, Lau R, Ciller C, Puyalto P, Gabarros A. Radiological predictors for extent of resection in pituitary adenoma surgery. A single-center study. World Neurosurg. 2017; 108: 436-446. https://doi.org/10.1016/j.wneu.2017.09.017. |
[25] | Shin W, Yan J, Abratte Cm, Vermeylen F, Caudill Ma. Choline intake exceeding current dietary recommendations preserves markers of cellular methylation in a genetic subgroup of folate-compromised men. J Nutr. 2010; 140(5): 975–980. |
[26] | Tjornstrand A, Gunnarsson K, Evert M, Holmberg E, Ragnarsson O, Rosen T, et al. The incidence rate of pituitary adenomas in western Sweden for the period 2001-2011. European journal of endocrinology / European Federation of Endocrine Scieties. 2014; 171(4): 519-26. |
[27] | Weaver Ic. Epigenetic programming by maternal behavior and pharmacological intervention. Nature versus nurture: let’s call the whole thing off. Epigenetics. 2007; 2(1): 22–28. |
[28] | Weaver Ic, Cervoni N, Champagne Fa, et al. Epigenetic programming by maternal behavior. Nat Neurosci. 2004; 7(8): 847–854. |
[29] | Zingg Jm, Jones Pa. Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis. Carcinogenesis. 1997; 18(5): 869–882. |